1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
FluoroPharma Medical, Inc.

FluoroPharma Medical, Inc.

FPMI
FluoroPharma Medical, Inc.US flagOther OTC
0.00
USD
- -
- -
6,852.00Market Cap
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
TTM
Revenue per Share
0.01
0.02
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.01
- -
- -
-0.08
-0.24
-0.18
-0.3
-0.16
-0.12
- -
-0.08
Free Cash Flow per Basic Share
-0.01
- -
- -
-0.04
-0.14
-0.15
-0.14
-0.13
-0.09
- -
-0.03
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.01
-0.01
-0.01
-0.67
-0.72
-0.74
-0.99
-1.01
-1.08
- -
-1.05
Tangible Book Value per Share
- -
- -
- -
-0.16
0.17
0.06
-0.05
-0.18
-0.27
- -
-0.31
Basic Weighted Avg Shares
11
11
11
13
18
23
24
29
30
- -
33
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-221.6
-8.44
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
-1
-3
-4
-6
-4
-3
-2
-2
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-65.56
-10.08
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
-2
3
1
-1
-5
-8
-10
-10
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
-2
3
1
-1
-5
-8
-10
-10
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-6.92
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'16
Sep'16
Dec'16
ST Debt
5
6
6
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
34
34
34
Market Capitalization
7
6
4

Working Capital

FRC

•

in mil. unless spec.
Jun'16
Sep'16
Dec'16
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
11
10
11
Payables & Accruals
4
4
4
ST Debt
5
6
6
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
42.86%
29.5%
Free Cash Flow
- -
-9.76%
-67.16%
Net Income, GAAP
- -
-4.43%
-35.21%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
148.49%
-8.82%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
-0.05
-0.07
-0.04
- -
-0.16
2015
-0.02
-0.05
- -
- -
-0.12
2016
-0.05
-0.03
0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Edward L. Lyons Jr.
Full Time Employees
4
Sector
Healthcare
Industry
Biotechnology
Address
8 Hillside Avenue Montclair NJ United States of America 07042
IPO Date
May 16, 2011
Website
fluoropharma.com
Similar Companies
Zota Health Care Limited (ZOTA.NS)
NervGen Pharma Corp. (NGENF)
HBM Holdings Limited (2142.HK)
TC Biopharm (Holdings) Plc (TCBPW)
Taysha Gene Therapies, Inc. (TSHA)
NuGenerex Immuno-Oncology, Inc. (NUGX)
Business
FluoroPharma Medical, Inc. (FPMI) is a biopharmaceutical company specializing in the discovery, development, and commercialization of molecular imaging pharmaceuticals, with initial applications in cardiology; its core products include clinical-stage candidates such as BFPET (18F-TPP), an imaging agent completed in Phase I trials for stress-testing in patients with presumptive or proven coronary artery disease (CAD), and CardioPET (18F-FCPHA), in Phase IIa trials to assess myocardial blood flow and metabolism in CAD patients; the company focuses on positron emission tomography (PET) agents for detecting and assessing acute and chronic CAD, inflamed atherosclerotic plaque, and other cardiovascular conditions. Headquartered in Montclair, New Jersey, and founded in 2003, FluoroPharma Medical operates primarily in the United States through its biopharmaceutical research and development segment, licensing technology from institutions like Massachusetts General Hospital to advance precision diagnostics for personalized medicine. The company previously acquired Ground Fluor Pharmaceuticals in June 2016 to bolster its fluorine chemistry capabilities for PET imaging; it received $0.6 million in funding from Platinum-Montaur Life Sciences in 2020 and continues development efforts amid a low market capitalization of approximately $5,500 as of late 2025, with no reported partnerships, new launches, or major strategic shifts in the last 1-2 years.